These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22168650)

  • 1. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
    Niessner A
    N Engl J Med; 2011 Dec; 365(24):2333; author reply 2335. PubMed ID: 22168650
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
    Pearson S; Troughton R; Richards AM
    N Engl J Med; 2011 Dec; 365(24):2334-5; author reply 2335. PubMed ID: 22168653
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
    Rosenstein R; Parra D
    N Engl J Med; 2011 Dec; 365(24):2334; author reply 2335. PubMed ID: 22168652
    [No Abstract]   [Full Text] [Related]  

  • 4. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
    Rose A
    N Engl J Med; 2011 Dec; 365(24):2333-4; author reply 2335. PubMed ID: 22168651
    [No Abstract]   [Full Text] [Related]  

  • 5. Stroke prevention in non-valvular atrial fibrillation with rivaroxaban.
    Cardiovasc J Afr; 2014; 25(4):196. PubMed ID: 25337613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(6):342-3. PubMed ID: 21135986
    [No Abstract]   [Full Text] [Related]  

  • 7. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
    Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
    Hosp Pract (1995); 2014 Aug; 42(3):17-25. PubMed ID: 25255403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.
    Patel MR; Hellkamp AS; Fox KA;
    N Engl J Med; 2016 Jul; 375(4):390-1. PubMed ID: 27433844
    [No Abstract]   [Full Text] [Related]  

  • 9. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.
    Powell JR
    N Engl J Med; 2016 Jul; 375(4):390. PubMed ID: 27433845
    [No Abstract]   [Full Text] [Related]  

  • 10. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.
    Patel MR; Hellkamp AS; Fox KA;
    N Engl J Med; 2016 Feb; 374(8):785-8. PubMed ID: 26839968
    [No Abstract]   [Full Text] [Related]  

  • 11. Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention.
    Hohnloser SH; Lopes RD
    Eur Heart J; 2014 Dec; 35(47):3323-5. PubMed ID: 25336222
    [No Abstract]   [Full Text] [Related]  

  • 12. [The ROCKET AF study].
    Capucci A; Prisco D
    G Ital Cardiol (Rome); 2012 Sep; 13(9):553-6. PubMed ID: 22825339
    [No Abstract]   [Full Text] [Related]  

  • 13. [Update on current care guidelines: atrial fibrillation].
    Käypä hoito -suosituksen päivitystiivistelmä
    Duodecim; 2012; 128(4):374-6. PubMed ID: 22448550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
    Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
    Circulation; 2016 Jul; 134(2):e7-8. PubMed ID: 27400902
    [No Abstract]   [Full Text] [Related]  

  • 15. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Apr; 30(4):645-53. PubMed ID: 24256067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
    Bouatou Y; El Biali M; Samer CF
    Circulation; 2016 Jul; 134(2):e3-4. PubMed ID: 27400900
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
    Imprialos K; Boutari C; Stavropoulos K
    Circulation; 2016 Jul; 134(2):e5-6. PubMed ID: 27400901
    [No Abstract]   [Full Text] [Related]  

  • 18. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
    Paikin JS; Manolakos JJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improvements in oral anticoagulant therapy for atrial fibrillation].
    Briongos Figuero S; García Santos-Gallego C; Badimón JJ
    Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the newer oral anticoagulants be withheld from patients with valvular AF?
    Dalen JE
    Chest; 2013 Aug; 144(2):369-370. PubMed ID: 23918100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.